HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cecchinato, V. Articles by Franchini, G. Search for Related Content PubMed PubMed Citation Articles by Cecchinato, V. Articles by Franchini, G.

Immune Activation Driven by CTLA-4 Blockade Augments Viral Replication at Mucosal Sites in Simian Immunodeficiency Virus Infection¹

Valentina Cecchinato^2,*, Elzbieta Tryniszewska^2,*,, Zhong Min Ma^¶, Monica Vaccari^*, Adriano Boasso, Wen-Po Tsai^*, Constantinos Petrovas^||, Dietmar Fuchs^#, Jean-Michel Heraud^3,*, David Venzon, Gene M. Shearer, Richard A. Koup^||, Israel Lowy^**, Christopher J. Miller^¶ and Genoveffa Franchini^4,*

^* Animal Models and Retroviral Vaccines Section, Experimental Immunology Branch, and Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD 20892; Department of Microbiology Diagnostics, Medical University of Bialystok, Bialystok, Poland; ^¶ California National Primate Research Center, University of California, Davis, CA 95616; ^|| Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892; ^# Division of Biological Chemistry Biocentre, Innsbruck Medical University, Innsbruck, Austria; and ^** Medarex, Bloomsbury, NJ 08804

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The importance of chronic immune activation in progression to AIDS has been inferred by correlative studies in HIV-infected individuals and in nonhuman primate models of SIV infection. Using the SIV_mac251 macaque model, we directly address the impact of immune activation by inhibiting CTLA-4, an immunoregulatory molecule expressed on activated T cells and a subset of regulatory T cells. We found that CTLA-4 blockade significantly increased T cell activation and viral replication in primary SIV_mac251 infection, particularly at mucosal sites, and increased IDO expression and activity. Accordingly, protracted treatment with anti-CTLA-4 Ab of macaques chronically infected with SIV_mac251 decreased responsiveness to antiretroviral therapy and abrogated the ability of therapeutic T cell vaccines to decrease viral set point. These data provide the first direct evidence that immune activation drives viral replication, and suggest caution in the use of therapeutic approaches for HIV infection in vivo that increase CD4⁺ T cell proliferation.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The pathogenesis of AIDS is not fully understood. One suggestion is that the ability of HIV to directly kill CD4⁺ T cells is central in the progressive demise of the immune system (1, 2, 3, 4, 5, 6, 7). An alternative proposal is that indirect effects linked to the host immune response, including production of proinflammatory cytokines and chemokines and increased CD4⁺ T cell activation and turnover, are pivotal to progression to AIDS (8, 9). Early loss of CCR5⁺CD4⁺ T cells from mucosal compartments, particularly the GALT, is another hallmark of HIV and SIV infection (1, 2, 3, 4, 5, 9), but "per se" may not be sufficient to determine disease development as it also occurs in nonpathogenic models of SIV infection (10, 11, 12). Thus, in the pathogenic SIV model, the relative contribution of direct CD4⁺ T cell killing and/or immune activation in disease progression, particularly at mucosal sites, remains unclear. In contrast, natural SIV infection of African nonhuman primates is asymptomatic and the lack of disease progression in this model has been linked to a low level of immune activation (13).

The initiation, maintenance, and contraction of adaptive immune responses are highly regulated by positive and negative molecules expressed on T cells, APCs, and CD4⁺CD25^highFoxP3⁺ regulatory T cells (T_reg).⁵ Upon TCR ligation, the relative expression of costimulatory CD28 molecules and negative regulatory CTLA-4 molecules dictate IL-2 production and T cell proliferation (14).

CD4⁺ T_reg that constitutively express CTLA-4, FoxP3, and glucocorticoid-induced TNFR have evolved to regulate immune responses and limit the tissue damage caused by CTL and proinflammatory cytokines (15). Through the induction of TGF-β and IDO, T_reg block cell cycle progression of T cells and reduce responsiveness to Ags (15). Thus, in principle, T_reg may delay or impair the elimination of pathogens and diminish responses to self-Ags, including those expressed by tumor cells.

In the case of HIV/SIV infection, the role of T_reg is unclear (16). Some reports conclude that T_reg or T_reg-associated markers are decreased in blood of HIV-1-infected individuals while others indicate an increase of T_reg in tissues (17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28). Even during the stages of SIV infection, the dynamics of T_reg distribution are unclear. Some reports have shown that the frequency of FoxP3⁺ T cells increases rapidly in tissues, suggesting that T_reg may impair the establishment of an effective adaptive immune response (22), whereas a recent study showed depletion of T_reg from the intestinal lamina propria during acute SIV infection, similar to that observed for CCR5⁺CD4⁺ T cells (29). Studies on gene expression in tissue RNA demonstrate a significant increase in the expansion of CTLA-4, IDO, and TGF-β in chronically infected macaques (19, 23). However, transient expression of these markers by newly activated T cells, not only by T_reg, precludes an accurate assessment of the importance of T_reg in AIDS pathogenesis using gene expression or phenotypic markers.

Because of the central role played by CTLA-4 in mediating both T_reg function and directly modulating T cell costimulation, we reasoned that the use of a blocking Ab to CTLA-4 could provide clues on the importance of T cell activation in the pathogenesis of AIDS. For our study, we have chosen the human MDX-010 Ab because of its known ability to block B7 binding to CTLA-4 (30). MDX-010 administration augments vaccine-induced immune responses in mice and macaques and, despite repeated inoculations, monkeys do not produce Abs to the human Ig (30).

In this study, we found that protracted CTLA-4 blockade treatment during both primary and chronic SIV_mac251 infection of macaques caused increased T cell activation and virus levels in tissues and plasma. Surprisingly, this treatment did not improve virus-specific T cell responses or decrease IDO activity. Similarly, the titers of Ab responses to SIV were not affected. Accordingly, CD4⁺ T cell loss at mucosal sites was exacerbated by the treatment.

Altogether, these data suggest that in SIV-infected macaques, the effect on T cell costimulation of anti-CTLA-4 Abs likely outweighed its effect on T_reg and highlight the importance of T cell activation in AIDS pathogenesis.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Animals

All animals were colony-bred Indian rhesus macaques (Macaca mulatta) obtained from Covance Research Products. The animals were housed and handled in accordance with the standards of the Association for the Assessment and Accreditation of Laboratory Animal Care International, and the study was reviewed and approved by the animal care and use committees at Advanced BioScience Laboratories. The care and use of the animals were in compliance with all relevant institutional (National Institutes of Health) guidelines.

At the time of purchase, all animals were in good health, 2–4 years of age, and weighed 4–9 kg. All animals were seronegative for SIV, simian T cell lymphotropic virus type 1, and herpes virus B. All animals were infected intrarectally with the same stock of SIV_mac251 as previously described (31). Antiretroviral therapy (ART), given in condition of mild sedation, was initiated at week 14 and halted at week 37 in the second study. ART consisted of i.v. administration of didanosine (10 mg/kg/day), oral administration of stavudine (d4T) twice a day (1.2 mg/kg/dose), and s.c. administration of (R)-9-(2-phosphonylmethoxypropyl) adenine (20 mg/kg/day). Treatment with MDX-010 (Medarex) was performed i.v. at a dose of 10 mg/kg. Repeated treatments of macaques with MDX-010 do not induce anti-human Abs. This was demonstrated by bridge ELISA (our unpublished data with Medarex). In this assay, the plates were coated with macaque sera, reacted with biotinylated MDX-010 and the complexes were revealed with streptavidin-alkaline phosphatase, eliminating concerns that the detection reagent reacted with the MDX-010. This assay has been accepted by the Food and Drug Administration as a means to validate the presence of anti-MDX-010 Abs in all of phase III studies performed.

RNA extraction, reverse transcription, and real-time PCR

Total RNA was extracted from macaques’ lymph nodes using the TRIzol LS Reagent (Invitrogen Life Technologies), according to the manufacturer’s instructions. RNA (1 µg) was reverse transcribed into first-strand cDNA in a 20-µl reaction containing 1 µM random hexanucleotide primers, 1 µM oligo dT, and 200 U Moloney murine leukemia virus reverse transcriptase (Promega).

cDNA quantification for IDO, SIV Gag RNA, and GAPDH was performed by real-time PCR conducted with the ABI Prism 7900HT (Applied Biosystems). All reactions were performed using a SYBR green PCR mix (Qiagen), according to the following thermal profile: denaturation at 95°C for 15 s, annealing at 60°C for 15 s, extension at 72°C for 15 s (data collection was performed during the extension step). Data analysis was performed with SDS2.1 software, provided with ABI Prism 7900HT (Applied Biosystems). Primer sequences were designed using the Primer3 software, available online (http://frodo.wi.mit.edu/cgi-bin/primer3/ primer3_www.cgi), and were previously described (23).

Viral load measurement

A real-time nucleic acid sequence-based amplification (NASBA) assay was used to quantitate SIV viral RNA in plasma. Plasma was clarified by centrifugation at 2,300 x g for 3 min. Clarified plasma (0.1 ml) was lysed in 0.9 ml of lysis buffer. For samples expected to have low viral load, the clarified plasma (0.5–1 ml) was centrifuged at 49,100 x g for 60 min. The virus pellet was then lysed in 1 ml of lysis buffer. Nucleic acid was isolated as described previously (32) and then analyzed by real-time NASBA as described previously (33). The real-time NASBA assay had a lower limit of sensitivity of 50 copies of RNA.

Preparation of lymphocytes from blood and tissues

Mononuclear cells from blood and lymph nodes were isolated by density-gradient centrifugation on Ficoll and resuspended in RPMI 1640 medium (Invitrogen Life Technologies) containing 10% FBS (R-10). Tissues from the rectum were treated with 1 mM Ultra Pure DTT (Invitrogen Life Technologies) for 30 min followed by incubation in calcium/magnesium-free HBSS (Invitrogen Life Technologies) three to four times for 60 min with stirring at room temperature to remove the epithelial layer. Lamina propria lymphocytes were separated following the removal of the epithelium and intraepithelial lymphocytes. The remaining tissue was cut into small pieces and incubated with collagenase D (400 U/ml; Boehringer Mannheim) and DNase (1 µg/ml; Invitrogen Life Technologies) for 2.5 h at 37°C in IMDM (Invitrogen Life Technologies) supplemented with 10% FBS and penicillin-streptomycin. The dissociated mononuclear cells were than placed over 42% Percoll (General Electric Healthcare) and centrifuged at 800 x g for 25 min at 4°C. Lamina propria lymphocytes were collected from the cell pellet.

Measurement of T cell number, activation, and memory phenotype

CD4⁺ and CD8⁺ counts were periodically determined on 100 µl of whole blood and by FACS analysis, according to the FACS/Lyse kit (BD Immunocytometry Systems) with minor modifications. Briefly, after incubating 10 µl of a mixture containing PerCP-CD4, allophycocyanin-CD8, PE-CD45, and FITC-CD3 mAbs (BD Biosciences) for 30 min at room temperature, red cells were lysed by adding 2 ml of FACS lysing solution (BD Biosciences) for 15 min. Samples were then centrifuged for 5 min at 1200 rpm at room temperature, washed (1% FCS, 0.05% NaN₃ in PBS), resuspended in 500 µl of wash buffer, and stored at 4°C until analysis using a FACSCalibur flow cytometer (BD Biosciences).

The frequency of activated T cells was measured by FACS analysis. Briefly, cells (1 x 10⁶) were surface stained with anti-human CD8β-PE (Immunotech), anti-human CD4-PerCP (BD Pharmingen), and anti-human CD69-allophycocyanin (BD Pharmingen). After 30 min of incubation in the dark at room temperature, cells were washed with cold 1% FCS in PBS and permeabilized with FACSPerm (BD Pharmingen) for 10 min at room temperature in the dark. Following two further washes, cells were intracellularly stained with FITC-conjugated anti-Ki67 (BD Pharmingen), incubated for 20 min at 37°C, fixed with 1% paraformaldehyde in PBS, and analyzed on a FACSCalibur.

The frequency of memory T cells in lymph nodes was determined by FACS analysis. Briefly, cells (1 x 10⁶) were surface stained with anti-human CD28-FITC (BD Pharmingen), anti-human CD8β-PE (Immunotech), anti-human CD95-PeCy5 (BD Pharmingen), and anti-human CD4-allophycocyanin (BD Pharmingen) and incubated for 30 min at room temperature in the dark. Cells were washed with cold 1% FCS in PBS, fixed with 1% paraformaldehyde in PBS, and analyzed on a FACSCalibur. For the analysis, the central memory and effector memory T cell populations were identified as CD28⁺CD95⁺ and CD28^–CD95⁺, respectively. The CCR7 marker was not used to define memory cells, as we have previously demonstrated that CD28 and CD95 identify similar T cell populations (34).

Tetramer staining

We screened rhesus macaques for the presence of the Mamu-A*01 allele using a PCR-based technique (35). Freshly prepared PBMC (5 x 10⁵/animal) were stained with anti-human CD3-FITC (BD Pharmingen), anti-human CD8-PerCP (BD Biosciences), and Mamu-A*01 tetrameric complexes refolded in the presence of a specific peptide and conjugated to allophycocyanin-labeled streptavidin (Beckman Coulter). Gag_181–189 CM9 (CTPYDINQM)-specific or Tat_28–35 SL8 (STPESANL)-specific tetramer was used.

After 30 min of incubation in the dark at room temperature, cells were washed with 1% FCS in PBS and fixed with 1% paraformaldehyde in PBS (pH 7.4). Samples were analyzed on a FACSCalibur (BD Biosciences), and the data are presented as percentage of tetramer⁺ cells in all CD3⁺CD8⁺ lymphocytes.

Tryptophan and kynurenine concentration measurement by HPLC

Detection of tryptophan and kynurenine was performed on plasma collected from animals by HPLC as previously described (36).

Intracellular cytokine (ICC) staining

ICC staining was performed using the anti-TNF-, -IFN , and -IL-2 Abs. A total of 10⁶ fresh PBMC in 1 ml of complete medium were incubated for 1 h at 37°C in the absence or presence of a pool of Gag, Nef, Tat, Rev, Pol, or Env peptides (1 µg/ml) and in the presence of CD28 and CD49d (1 µg/ml each) in a 5-ml round-bottom tube. After addition of 10 µg/ml brefeldin A (Sigma-Aldrich), cells were incubated for 5 h at 37°C and processed for surface and ICC staining. Briefly, cells were washed with 1% FCS in PBS, surface stained for 20 min with CD8β-PE (Immunotech) and CD4-PerCP (BD Biosciences), washed again, and fixed and permeabilized with Cytofix/Cytoperm (BD Pharmingen) for 20 min at 4°C in the dark. Following two further washes in Perm/Wash buffer (BD Pharmingen), cells were intracellularly stained with FITC-conjugated anti-IL-2 and allophycocyanin-conjugated anti-IFN- or allophycocyanin-conjugated-TNF- (BD Pharmingen), incubated for 20 min at 37°C, fixed with 1% paraformaldehyde in PBS, and analyzed on a FACSCalibur.

Immunohistochemistry and immunofluorescent Ab labeling of tissue sections

Tissue was fixed in 4% paraformaldehyde (Electron Microscopy Sciences) and embedded in paraffin. All slides were stained using the Autostainer (DakoCytomation). TBS with Tween 20 (DakoCytomation) was used for all washes and Ab diluent (DakoCytomation), 5% BSA/TBS, or 2% horse serum/TBS was used for all mAb dilutions. The primary Abs used included polyclonal anti-CD3 rabbit serum (DakoCytomation), mAb anti-CD4 mouse serum (clone IF6; Vector Laboratories), polyclonal anti-FoxP3 rabbit serum (Abcam), polyclonal anti-CD8 rabbit serum (DBS), and polyclonal anti-Ki67 rabbit serum (Lab Vision). For all primary Abs, slides were subjected to an Ag-retrieval step consisting of incubation in AR10 (Biogenex) for 2 min at 123°C in the Digital Decloaking Chamber (Biocare Medical) followed by cooling to 90°C before rinsing in running water and a final buffer rinse. Primary Abs were replaced by normal rabbit IgG (Zymed Laboratories) or mouse IgG (DakoCytomation) and included with each staining series as the negative control. For double-label immunofluorescence, primary Abs were diluted in BSA/monkey serum/TBS. Nonspecific binding sites were blocked with 10% goat serum and Tween 20 in PBS (Background Eraser; Biocare Medical). Binding of the primary Abs was detected simultaneously using Alexa Fluor 488-labeled polyclonal goat anti-rabbit IgG (Molecular Probes) and Alexa Fluor 568-labeled polyclonal goat anti-mouse IgG (Molecular Probes) for 1 h. Nonspecific binding sites were further blocked by the addition of a 30-min incubation in 5% BSA/TBS between the first primary Ab incubation and detection reagents, and the addition of a second primary Ab and detection reagents. All slides were coverslipped using Prolong Gold with 4',6-diamidino-2-phenylindole dihydrochloride hydrate (DAPI; Molecular Probes) to stain nuclei. All the control experiments gave appropriate results with minimal nonspecific staining (data not shown).

Slides were visualized with epifluorescent illumination using a Zeiss Axioplan 2 microscope (Carl Zeiss) and appropriate filters. Digital images were captured and analyzed by using a Zeiss Axiocam System and Openlab software (Inprovision).

Quantitative image analysis

The number of positive mAb-labeled cells/mm² of tissue sample was quantified using a Zeiss AxioCam HRc digital camera mounted on a Zeiss microscope (Carl Zeiss) fitted with a x40 plan neofluar objective and a polarizing filter cube with appropriate filters (Omega Optical). Digital images were captured with Openlab software. One section per tissue with representative histomorphologic components (cortex, paracortex, follicles, medulla for lymph nodes; and epithelium, lamina propria and muscularis mucosa for rectum) was analyzed. Five high-power (x40) microscope fields of the T cell-rich zone (paracortex) per lymph node section and five high-power fields of lamina propria from rectal sections were randomly chosen and captured digitally with the system described above. Each captured field includes an area of 0.04 mm². Only clearly positive cells with distinctly labeled nuclei (DAPI) and bright staining were considered positive. Individual positive cells in the five captured high-power microscope fields of the immunohistochemical-stained tissue sections were counted manually by a single observer. The numbers of positive cells are presented as cells/mm². All samples were analyzed by an operator who was blinded to the experimental design described in Fig. 1.

View larger version (26K): [in this window] [in a new window]   FIGURE 1. SIV primary infection: study design and tissue collection. All macaques were infected with SIVmac251 by the intrarectal route, as previously described (31 ). Macaques were treated or not at the times indicated with MDX-010. The time of rectal or lymph node biopsy is indicated with symbols: *, Mamu-A*01+ macaques. The MDX-010 Ab was given i.v. at 10 mg/kg/dose; d, days.

Statistical analyses for mRNA expression, tryptophan and kynurenine ratio, and lymph node viral load were performed using SPSS 13.0 software. Differences between groups were assessed by nonparametric Mann-Whitney U test. Differences before and after treatment within the same group were assessed using the Wilcoxon test. All p values shown in the text and figures are two tailed.

	Results

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
CTLA-4 blockade increases T cell activation in early SIV infection

Ten macaques were enrolled in the first study (Fig. 1). The animals were divided into two groups of five animals each and were all exposed intrarectally to SIV_mac251, as previously described (31). Five animals received four consecutive inoculations, 3 wk apart at a dose of 10 mg/kg MDX-010, a blocking Ab against human CTLA-4. The first inoculation of Ab was given 4 days before challenge exposure to SIV_mac251 to allow for adequate tissue distribution of the Abs. This dose of MDX-010 was chosen because of its ascertained biological effect in macaques (23). To assess the effect of treatment not only in blood but also at mucosal sites, we obtained blood, rectal biopsies, and axillary and inguinal lymph node biopsies at the times indicated in Fig. 1.

CTLA-4 expression is constitutive on T_reg and is induced transiently on CD4⁺ and CD8⁺ T cells upon T cell activation. Because activation of CD4⁺ T cells could provide more targets for SIV infection and increased viral replication, we quantified the total number of T cells, and of T cells that entered the cell cycle (expressing Ki67) in blood and tissues over time. The total number of CD3⁺CD4⁺ T cells did not change significantly over time in blood, lymph nodes, or rectal mucosa of the treated macaques (Fig. 2, A–C). However, there was a significant decrease in the absolute number of CD4⁺Ki67⁺ T cells in rectal mucosa (p = 0.028) but not in lymph nodes by week 14 (Fig. 2, D and E), suggesting that the loss of CD4⁺ T cells occurs faster in MDX-010-treated macaques. The fact that CD4⁺CCR5⁺ T cells, the targets for SIV infection, were also significantly decreased (p = 0.037) at mucosal sites in the treated group (Fig. 2F), and that CD4⁺ effector cells were maintained at higher numbers in the tissues of the untreated macaques (p = 0.05) (Fig. 2G) argues in favor of a more pronounced loss of CD4⁺ T cells due to direct viral cytopathic effect. Likewise, anti-CTLA-4 treatment did not result in a significant change in the absolute number of CD8⁺ T cells in blood (Fig. 2H), lymph nodes, and rectal mucosa (Fig. 2, I and J). Quantitation of the total number or frequency of activated CD8⁺Ki67⁺ T cells in intact tissues by immunohistochemistry or by analysis of single-cell suspension revealed a significant increase in lymph nodes by week 10 (p = 0.039), and, to a lesser extent, at mucosal sites (Fig. 2, K and L). Altogether, these results indicate that CTLA-4 blockade induced cell cycle entry of both CD4⁺ and CD8⁺ T cell subsets, but that the appropriate enumeration of activated CD4⁺ T cells may be precluded because they rapidly become infected and consequently lost.

View larger version (40K): [in this window] [in a new window]   FIGURE 2. MDX-010 treatment increases T cell activation and exacerbates CCR5+CD4+ T cell loss in tissues. Mean values (±SE) of the absolute CD3+CD4+ T cells/mm3 in blood (A). Total number of CD3+CD4+ T cells/mm2 in lymph nodes (B) and rectal mucosa (C). Total number of CD4+Ki67+ T cell numbers/mm2 in lymph nodes (D) and rectal mucosa (E). F, Frequency of CCR5+CD4+ T cells in rectal mucosa before and after challenge exposure to SIVmac251. For the after challenge analysis, the geometric mean of the frequency of CCR5+CD4+ T cells at weeks 7–14 is shown for each animal. The bars represent the mean value in each group. G, Mean value (+SE) of the frequency of effector memory CD4+ T cells in lymph nodes of animals over time. Absolute number of CD3+CD8+ T cells/mm3 in blood (H) or CD3+CD8+ T cells/mm2 in lymph nodes (I) and rectal mucosa (J). Percentage (mean value + SE) of CD8+Ki67+ T cells in lymph nodes (K) and absolute number of CD8+Ki67+ T cells/mm2 in rectal mucosa (L). All the data in B–E and H–J and L were obtained by immunohistochemistry counting of the number of CD4+ or CD8+ T cells/mm2 of tissues. Lymph nodes were either axillary or inguinal. Horizontal bars in the scatter dot plots correspond to the median.

To evaluate the effect of MDX-010 treatment on viral replication, we measured virus RNA levels not only in plasma but also in lymph nodes and rectal biopsies of all animals. Both groups mounted similar plasma virus levels during the first 3 wk of infection (Fig. 3, A and B). However, the group treated with MDX-010 had significantly higher levels of plasma virus in the interval between weeks 8 and 14 (p = 0.04) (Fig. 3C), but surprisingly this difference did not reach significance in lymph nodes (Fig. 3D). In contrast, virus RNA levels were higher in rectal biopsies of the treated macaques (p = 0.041), implying an association between increased T cell activation and virus levels (Fig. 3E). Indeed, we found a negative correlation between the number of activated CD4⁺ T cells in blood and plasma virus levels (Fig. 3F), further supporting the notion that activated T cells may become infected and die.

View larger version (31K): [in this window] [in a new window]   FIGURE 3. Systemic and mucosal virus levels. A and B, Plasma SIV RNA level over time for each macaque in the control and MDX-010 groups, respectively. *, Mamu-A*01+. C, Geometric mean values of virus levels in the two groups. Statistical analysis by the Wei-Johnson test counting weeks 9, 10, 12, and 14 demonstrated significantly higher viremia in macaques treated with MDX-010 (p = 0.032). Similarly, from weeks 8 to 14, the difference between the two groups was significant (p = 0.040), as indicated in the figure. D and E, SIV Gag RNA levels normalized on GAPDH in RNA of lymph nodes (D) and rectal mucosa (E) of control animals () and MDX-010-treated macaques (). Statistical analysis was performed using the repeated measures ANOVA. Horizontal bars in the scatter dot plots correspond to the median. F, Correlative analysis between the number of activated CD4+ T cells in blood and plasma virus levels at week 14 postinfection.

View larger version (28K): [in this window] [in a new window]   FIGURE 4. Virus-specific immune responses in blood and tissues. A and B, Mean values (+SE) of the absolute number of CM9+ or SL8+tetramer+ T cells/mm3 of blood (A) and of the frequency of these responses in rectal mucosa (B) following exposure to SIVmac251 in treated and untreated macaques. C, Total number of CD4+ and CD8+ T cells producing IFN-, TNF-, and IL-2 following in vitro stimulation with the entire SIV Gag peptide pool in the blood of macaques during primary infection. D, Titers of serum-binding Abs to gp120 measured by ELISA. Horizontal bars in the scatter dot plot correspond to the median.

IDO, an enzyme that converts tryptophan into kynurenine and halts T cell proliferation, is expressed at high level in tissues of HIV/SIV-infected hosts (19, 20, 38). Because IDO is induced by the engagement of CTLA-4 expressed on T_reg or activated T cells to the CD80 or CD86 molecules on the surface of APC (15), analysis of IDO level provided an opportunity to assess whether the high level of IDO in SIV infection could be lowered by CTLA-4 blockade. CTLA-4 blockade was associated with a significant increase rather than a decrease in IDO expression in rectal tissues following all treatments (p = 0.0049) (Fig. 5A), and, accordingly, the overall rate of IDO activity, measured as a ratio between plasma concentration of kynurenine to tryptophan, was also significantly increased in MDX-010-treated macaques (p < 0.05 at 4, 8, and 10 wk) (Fig. 5B).

View larger version (24K): [in this window] [in a new window]   FIGURE 5. Increased IDO expression and activity and decreased FoxP3+CD4+ T cells in MDX-010-treated macaques. A, IDO RNA levels were measured by RT-PCR in rectal mucosa. Horizontal bars in the smaller plot correspond to the median. B, The kynurenine-to-tryptophan ratio was measured in plasma at the times indicated. *, Significant (p < 0.05) differences in the two groups. The data are expressed as mean value (±SE). Total number of CD4+FoxP3+ T cells/mm2 in lymph nodes (C) and rectal mucosa (D).

CTLA-4 blockade reduces responsiveness to ART and abrogates the virological benefit of vaccination

During SIV infection, primary virus-induced immune activation may confound a possible therapeutic effect of CTLA-4 blockade. Indeed, a short treatment with MDX-010 of SIV-infected macaques treated with ART resulted in increased immune activation but was associated with a decrease rather than an increase in viral replication in tissues (23). Therefore, we investigated the safety of a protracted treatment with MDX-010 in macaques and whether, in the presence of ART, this treatment could provide an immunological and virological benefit. Furthermore, because the inhibitory effect of CTLA-4 is more evident during secondary rather than primary immune response (41), we combined treatment of MDX-010 with vaccination. We designed a study whereby macaques were infected intrarectally with SIV_mac251 and treated with ART at week 14 after infection (Fig. 6A). Two groups of macaques were treated with four inoculations of MDX-010 5 wk apart at the same dose used in primary infection (10 mg/kg). In addition, one of those groups also received modified vaccinia Ankara-based vaccines expressing the structural and regulatory genes of SIV (Fig. 6A) 4 days after the first three inoculations of MDX-010. As a control, one group was vaccinated in an identical manner in the absence of MDX-010 Ab treatment (Fig. 6A). Vaccination of SIV-infected macaques with this vaccine modality usually results in a decrease of viral set point, when compared with the pre-ART level, by 1 log in virus plasma level after ART is suspended (31, 42, 43). We found that infected macaques treated with MDX-010 (groups 1 and 2) predominantly did not respond to ART (Fig. 6B) in contrast to those in group 3, which predominantly responded (Fig. 6C). Furthermore, when the vaccine effect was evaluated in macaques that effectively responded to therapy (three in the MDX-010-treated group and four in the vaccine-only group), we found that vaccination alone decreased the set point by 1 log, as expected (Fig. 6D). However, when vaccination was combined with MDX-010, the reduction of virus level following suspension of ART became less evident (Fig. 6D). These results suggested that CTLA-4 blockade may have increased T cell activation in the presence of ART and decreased ART responsiveness. Indeed, similar to our previous report (23), MDX-010 treatment of chronically infected macaques increased Ki67 on CD4⁺ and CD8⁺ T cells in blood and lymph nodes (data not shown), even in the presence of ART.

View larger version (38K): [in this window] [in a new window]   FIGURE 6. MDX-010 decreases ART responsiveness and abrogates the vaccine effect in chronically infected macaques. A, Schematic representation of the second study design and animal groups. MDX-010 was given at weeks 22, 27, 32, and 37 at a dose of 10 mg/kg. Vaccination was performed with two inoculations of modified vaccinia Ankara-expressing Gag, Pol, Env, and retanef (56 ) 4 days after the administration of the Ab in each case. *, Mamu-A*01+. Plasma virus levels during the study in all the MDX-010-treated macaques (groups 1 and 2) (B) and in macaques vaccinated only (C). *, Mamu-A*01+. D, Plasma virus levels in macaques M674, M601, M608 from group 1 and M677, M640, M647, and M649 from group 3. These animals were selected to evaluate the vaccine effect as they maintained adequate suppression of viral replication during ART treatment.

View larger version (28K): [in this window] [in a new window]   FIGURE 7. Virus-specific immune responses induced by vaccination. CD4+ and CD8+ T cell responses (A and B, respectively) measured as IL-2 or TNF- and IFN- production following vaccination and ART suspension were evaluated in the same macaques used in Fig. 6D whose viremia remained suppressed during ART. These animals were selected to limit the confounding factor of overt viral replication on the vaccine immunogenicity. In these experiments, almost the entire SIV proteome was used as stimulus.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

Our study demonstrates that CTLA-4 blockade significantly increases viral replication and CD4⁺ T cell loss, particularly at mucosal sites, and does not significantly restore virus-specific immune responses. The increase in T cell activation was documented by several methods, including quantitating the absolute number of CD8⁺ T cells in tissues by immunohistochemistry. In the case of activated CD4⁺ T cells, we observed a significant decrease in their absolute number in tissues, concomitant with a significant increase in viral replication in the same locale, suggesting that inhibition of CTLA-4 likely exacerbates viral replication and CD4⁺ T cell loss. Paradoxically, CTLA-4 blockade increased the tissue expression and activity of IDO, an enzyme induced by the engagement of B7 by CTLA-4 (48, 49) and, directly, by exposure of APC to HIV virions (39, 40). IDO activity is strictly associated with activation of the immune system and can be induced by cytokines such as types I and II IFN (50, 51). HIV is also able to directly induce IDO expression in vitro (39); therefore, it is possible that the increase in IDO expression and activity observed in the infected macaques treated with MDX-010 is due to the high level of viral replication. An alternative explanation, however, could be that the anti-CTLA-4 Ab may work as an agonist in vivo and increase T_reg activity.

Importantly, in this macaque model, even when viral replication is suppressed by ART, protracted treatment with MDX-010 resulted in increased T cell activation and an apparent diminished responsiveness to ART, and, again, no increase in the SIV-specific virus-induced or vaccine-induced immune response was observed. A caveat in this animal model, however, is that ART treatment of macaques does not include protease inhibitors that greatly contribute to suppression of viral replication in HIV-1-infected individuals. Therefore, these results may not be directly applicable to patients treated with optimal ART regimens. Nevertheless, the evidence that we provide supports the notion that, by decreasing the threshold of T cell activation, particularly when viral replication is not fully controlled, CTLA-4 blockade in vivo may provide more target cells to the virus.

In this study, we have not directly addressed the role of T_reg"per se" in SIV infection, because CTLA-4 is also expressed on activated T cells. However, treatment with MDX-010 in humans is frequently associated with manifestation of autoimmunity, including erythematosus rash, generation of autoantibodies, colitis, hypophysitis, and uveitis, suggesting its ability to break tolerance to T cell Ags (52). Of notice, MDX-010 treatment affected T cell activation and viral replication, particularly at mucosal sites, where T_reg are likely to maintain a state of controlled inflammation, given the continual exposure to alimentary and bacterial Ags (53).

We believe that the fact that CTLA-4 blockade in SIV_mac251-infected macaques did not result in an increase of immune response elicited by viral infection or vaccination in blood and tissues suggest a predominant role for immune activation, particularly at mucosal sites, and a limited contribution of T_reg to the suppression of immune responses in vivo. The study presented here therefore complements work of others demonstrating that the low level of immune activation in Sooty may be related to the lack of progression to AIDS, despite the high levels of SIV replication (13).

The direct demonstration in our work that immune activation, particularly at mucosal sites, increases both local and systemic viral replication underscores the importance of paying attention to the gastrointestinal immune system in AIDS pathogenesis, as also proposed by others (54), and highlights the usefulness of macaque models for dissecting underlying pathogenic mechanisms of disease induction and for the development of therapeutic intervention for HIV (55).

	Acknowledgments

 
We thank Steven Snodgrass for editorial assistance; Claire Chougnet, Jan Andersson, and Jakob Nilsson for helpful discussion; and Phillip Markham, Jim Treece, Deborah Weiss, Eun Lee, and Sharon Orndorff at Advanced BioScience Laboratories for help with the animal study.

	Disclosures

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Israel Lowy is an employee of Medarex, Bloomsbury, NJ, whose product, MDX-010, was used in this manuscript.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.

² V.C. and E.T. contributed equally.

³ Current address: World Health Organization-National Influenza Laboratory, Institut Pasteur de Madagascar, Antananarivo, Madagascar.

⁴ Address correspondence and reprint requests to Dr. Genoveffa Franchini, Animal Models and Retroviral Vaccines Section, National Cancer Institute, 9000 Rockville Pike, 41/D804, Bethesda, MD 20892-5065. E-mail address: franchig{at}mail.nih.gov

⁵ Abbreviations used in this paper: T_reg, regulatory T cell; ART, antiretroviral therapy; NASBA, nucleic acid sequence-based amplification; ICC, intracellular cytokine.

Received for publication November 8, 2007. Accepted for publication February 17, 2008.

	References

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 

1. Mattapallil, J. J., D. C. Douek, B. Hill, Y. Nishimura, M. Martin, M. Roederer. 2005. Massive infection and loss of memory CD4⁺ T cells in multiple tissues during acute SIV infection. Nature 434: 1093-1097. [Medline]
2. Mehandru, S., M. A. Poles, K. Tenner-Racz, A. Horowitz, A. Hurley, C. Hogan, D. Boden, P. Racz, M. Markowitz. 2004. Primary HIV-1 infection is associated with preferential depletion of CD4⁺ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200: 761-770. [Abstract/Free Full Text]
3. Mehandru, S., M. A. Poles, K. Tenner-Racz, V. Manuelli, P. Jean-Pierre, P. Lopez, A. Shet, A. Low, H. Mohri, D. Boden, et al 2007. Mechanisms of gastrointestinal CD4⁺ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J. Virol. 81: 599-612. [Abstract/Free Full Text]
4. Smit-McBride, Z., J. J. Mattapallil, M. McChesney, D. Ferrick, S. Dandekar. 1998. Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4⁺ T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J. Virol. 72: 6646-6656. [Abstract/Free Full Text]
5. Veazey, R. S., M. DeMaria, L. V. Chalifoux, D. E. Shvetz, D. R. Pauley, H. L. Knight, M. Rosenzweig, R. P. Johnson, R. C. Desrosiers, A. A. Lackner. 1998. Gastrointestinal tract as a major site of CD4⁺ T cell depletion and viral replication in SIV infection. Science 280: 427-431. [Abstract/Free Full Text]
6. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586. [Abstract]
7. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126. [Medline]
8. Grossman, Z., M. Meier-Schellersheim, W. E. Paul, L. J. Picker. 2006. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat. Med. 12: 289-295. [Medline]
9. Li, Q., L. Duan, J. D. Estes, Z. M. Ma, T. Rourke, Y. Wang, C. Reilly, J. Carlis, C. J. Miller, A. T. Haase. 2005. Peak SIV replication in resting memory CD4⁺ T cells depletes gut lamina propria CD4⁺ T cells. Nature 434: 1148-1152. [Medline]
10. Gordon, S. N., N. R. Klatt, S. E. Bosinger, J. M. Brenchley, J. M. Milush, J. C. Engram, R. M. Dunham, M. Paiardini, S. Klucking, A. Danesh, et al 2007. Severe depletion of mucosal CD4⁺ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J. Immunol. 179: 3026-3034. [Abstract/Free Full Text]
11. Milush, J. M., J. D. Reeves, S. N. Gordon, D. Zhou, A. Muthukumar, D. A. Kosub, E. Chacko, L. D. Giavedoni, C. C. Ibegbu, K. S. Cole, et al 2007. Virally induced CD4⁺ T cell depletion is not sufficient to induce AIDS in a natural host. J. Immunol. 179: 3047-3056. [Abstract/Free Full Text]
12. Pandrea, I. V., R. Gautam, R. M. Ribeiro, J. M. Brenchley, I. F. Butler, M. Pattison, T. Rasmussen, P. A. Marx, G. Silvestri, A. A. Lackner, et al 2007. Acute loss of intestinal CD4⁺ T cells is not predictive of simian immunodeficiency virus virulence. J. Immunol. 179: 3035-3046. [Abstract/Free Full Text]
13. Silvestri, G., M. Paiardini, I. Pandrea, M. M. Lederman, D. L. Sodora. 2007. Understanding the benign nature of SIV infection in natural hosts. J. Clin. Invest. 117: 3148-3154. [Medline]
14. Sperling, A. I., J. A. Bluestone. 1996. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol. Rev. 153: 155-182. [Medline]
15. Miyara, M., S. Sakaguchi. 2007. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 13: 108-116. [Medline]
16. Boasso, A., M. Vaccari, J. Nilsson, G. M. Shearer, J. Andersson, V. Cecchinato, C. Chougnet, G. Franchini. 2006. Do regulatory T-cells play a role in AIDS pathogenesis?. AIDS Rev. 8: 141-147. [Medline]
17. Aandahl, E. M., J. Michaelsson, W. J. Moretto, F. M. Hecht, D. F. Nixon. 2004. Human CD4⁺ CD25⁺ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J. Virol. 78: 2454-2459. [Abstract/Free Full Text]
18. Apoil, P. A., B. Puissant, F. Roubinet, M. Abbal, P. Massip, A. Blancher. 2005. FOXP3 mRNA levels are decreased in peripheral blood CD4⁺ lymphocytes from HIV-positive patients. J. Acquir. Immune. Defic. Syndr. 39: 381-385. [Medline]
19. Boasso, A., M. Vaccari, A. Hryniewicz, D. Fuchs, J. Nacsa, V. Cecchinato, J. Andersson, G. Franchini, G. M. Shearer, C. Chougnet. 2007. Regulatory T cell markers, indoleamine (2,3)-dioxygenase and virus levels in spleen and gut during progressive SIV infection. J. Virol. 81: 11593-11603. [Abstract/Free Full Text]
20. Boasso, A., G. M. Shearer. 2007. How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation. Curr. Drug Metab. 8: 217-223. [Medline]
21. Epple, H. J., C. Loddenkemper, D. Kunkel, H. Troger, J. Maul, V. Moos, E. Berg, R. Ullrich, J. D. Schulzke, H. Stein, et al 2006. Mucosal but not peripheral FOXP3⁺ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood 108: 3072-3078. [Abstract/Free Full Text]
22. Estes, J. D., Q. Li, M. R. Reynolds, S. Wietgrefe, L. Duan, T. Schacker, L. J. Picker, D. I. Watkins, J. D. Lifson, C. Reilly, et al 2006. Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J. Infect. Dis. 193: 703-712. [Medline]
23. Hryniewicz, A., A. Boasso, Y. Edghill-Smith, M. Vaccari, D. Fuchs, D. Venzon, J. Nacsa, M. R. Betts, W. P. Tsai, J. M. Heraud, et al 2006. CTLA-4 blockade decreases TGF-β, indoleamine 2,3- dioxygenase, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 108: 3834-3842. [Abstract/Free Full Text]
24. Kinter, A. L., M. Hennessey, A. Bell, S. Kern, Y. Lin, M. Daucher, M. Planta, M. McGlaughlin, R. Jackson, S. F. Ziegler, A. S. Fauci. 2004. CD25⁺CD4⁺ regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4⁺ and CD8⁺ HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J. Exp. Med. 200: 331-343. [Abstract/Free Full Text]
25. Nilsson, J., A. Boasso, P. A. Velilla, R. Zhang, M. Vaccari, G. Franchini, G. M. Shearer, J. Andersson, C. Chougnet. 2006. HIV-1 driven regulatory T cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 108: 3808-3817. [Abstract/Free Full Text]
26. Nixon, D. F., E. M. Aandahl, J. Michaelsson. 2005. CD4⁺CD25⁺ regulatory T cells in HIV infection. Microbes Infect. 7: 1063-1065. [Medline]
27. Tsunemi, S., T. Iwasaki, T. Imado, S. Higasa, E. Kakishita, T. Shirasaka, H. Sano. 2005. Relationship of CD4⁺CD25⁺ regulatory T cells to immune status in HIV-infected patients. AIDS 19: 879-886. [Medline]
28. Weiss, L., V. Donkova-Petrini, L. Caccavelli, M. Balbo, C. Carbonneil, Y. Levy. 2004. Human immunodeficiency virus-driven expansion of CD4⁺CD25⁺ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 104: 3249-3256. [Abstract/Free Full Text]
29. Chase, A. J., A. R. Sedaghat, J. R. German, L. Gama, M. C. Zink, J. E. Clements, R. F. Siliciano. 2007. Severe depletion of CD4⁺CD25⁺ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute SIV infection. J. Virol. 81: 12748-12757. [Abstract/Free Full Text]
30. Keler, T., E. Halk, L. Vitale, T. O’Neill, D. Blanset, S. Lee, M. Srinivasan, R. F. Graziano, T. Davis, N. Lonberg, A. Korman. 2003. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol. 171: 6251-6259. [Abstract/Free Full Text]
31. Hryniewicz, A., D. A. Price, M. Moniuszko, A. Boasso, Y. Edghill-Spano, S. M. West, D. Venzon, M. Vaccari, W. P. Tsai, E. Tryniszewska, et al 2007. Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques. J. Immunol. 178: 3492-3504. [Abstract/Free Full Text]
32. Romano, J. W., R. N. Shurtliff, E. Dobratz, A. Gibson, K. Hickman, P. Markham, R. Pal. 2000. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J. Virol. Methods 86: 61-70. [Medline]
33. Malkevitch, N. V., L. J. Patterson, M. K. Aldrich, Y. Wu, D. Venzon, R. H. Florese, V. S. Kalyanaraman, R. Pal, E. M. Lee, J. Zhao, et al 2006. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8⁺ T cell responses. Virology 353: 83-98. [Medline]
34. Vaccari, M., C. J. Trindade, D. Venzon, M. Zanetti, G. Franchini. 2005. Vaccine-induced CD8⁺ central memory T cells in protection from simian AIDS. J. Immunol. 175: 3502-3507. [Abstract/Free Full Text]
35. Knapp, L. A., E. Lehmann, M. S. Piekarczyk, J. A. Urvater, D. I. Watkins. 1997. A high frequency of Mamu-A*01 in the rhesus macaque detected by PCR-SSP and direct sequencing. Tissue Antigens 50: 657-661. [Medline]
36. Widner, B., E. R. Werner, H. Schennach, H. Wachter, D. Fuchs. 1997. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin. Chem. 43: 2424-2426. [Free Full Text]
37. Mothe, B. R., H. Horton, D. K. Carter, T. M. Allen, M. E. Liebl, P. Skinner, T. U. Vogel, S. Fuenger, K. Vielhuber, W. Rehrauer, et al 2002. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J. Virol. 76: 875-884. [Abstract/Free Full Text]
38. Schroecksnadel, K., R. Zangerle, R. Bellmann-Weiler, K. Garimorth, G. Weiss, D. Fuchs. 2007. Indoleamine-2, 3-dioxygenase and other interferon--mediated pathways in patients with human immunodeficiency virus infection. Curr. Drug Metab. 8: 225-236. [Medline]
39. Boasso, A., J. P. Herbeuval, A. W. Hardy, S. A. Anderson, M. J. Dolan, D. Fuchs, G. M. Shearer. 2007. HIV inhibits CD4⁺ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109: 3351-3359. [Abstract/Free Full Text]
40. Grant, R. S., H. Naif, S. J. Thuruthyil, N. Nasr, T. Littlejohn, O. Takikawa, V. Kapoor. 2000. Induction of indoleamine 2,3-dioxygenase in primary human macrophages by HIV-1. Redox. Rep. 5: 105-107. [Medline]
41. Chambers, C. A., T. J. Sullivan, T. Truong, J. P. Allison. 1998. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8⁺ T cells. Eur. J. Immunol. 28: 3137-3143. [Medline]
42. Hel, Z., D. Venzon, M. Poudyal, W.-P. Tsai, L. Giuliani, R. Woodward, C. Chougnet, G. M. Shearer, J. D. Altman, D. I. Watkins, et al 2000. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV₂₅₁ infection of macaques. Nat. Med. 6: 1140-1146. [Medline]
43. Tryniszewska, E., J. Nacsa, M. G. Lewis, P. Silvera, D. Montefiori, D. Venzon, Z. Hel, R. W. Parks, M. Moniuszko, J. Tartaglia, et al 2002. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J. Immunol. 169: 5347-5357. [Abstract/Free Full Text]
44. Kornfeld, C., M. J. Ploquin, I. Pandrea, A. Faye, R. Onanga, C. Apetrei, V. Poaty-Mavoungou, P. Rouquet, J. Estaquier, L. Mortara, et al 2005. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J. Clin. Invest. 115: 1082-1091. [Medline]
45. Oswald-Richter, K., S. M. Grill, N. Shariat, M. Leelawong, M. S. Sundrud, D. W. Haas, D. Unutmaz. 2004. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol. 2: E198[Medline]
46. Pereira, L. E., F. Villinger, N. Onlamoon, P. Bryan, A. Cardona, K. Pattanapanysat, K. Mori, S. Hagen, L. Picker, A. A. Ansari. 2007. Simian immunodeficiency virus (SIV) infection influences the level and function of regulatory T cells in SIV-infected rhesus macaques but not SIV-infected sooty mangabeys. J. Virol. 81: 4445-4456. [Abstract/Free Full Text]
47. Egen, J. G., M. S. Kuhns, J. P. Allison. 2002. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3: 611-618. [Medline]
48. Fallarino, F., U. Grohmann, K. W. Hwang, C. Orabona, C. Vacca, R. Bianchi, M. L. Belladonna, M. C. Fioretti, M. L. Alegre, P. Puccetti. 2003. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4: 1206-1212. [Medline]
49. Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M. L. Belladonna, R. Bianchi, M. C. Fioretti, P. Puccetti. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3: 1097-1101. [Medline]
50. Mellor, A. L., D. H. Munn. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4: 762-774. [Medline]
51. Schrocksnadel, K., B. Wirleitner, C. Winkler, D. Fuchs. 2006. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta 364: 82-90. [Medline]
52. Peggs, K. S., S. A. Quezada, A. J. Korman, J. P. Allison. 2006. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18: 206-213. [Medline]
53. Makita, S., T. Kanai, Y. Nemoto, T. Totsuka, R. Okamoto, K. Tsuchiya, M. Yamamoto, H. Kiyono, M. Watanabe. 2007. Intestinal lamina propria retaining CD4⁺CD25⁺ regulatory T cells is a suppressive site of intestinal inflammation. J. Immunol. 178: 4937-4946. [Abstract/Free Full Text]
54. Brenchley, J. M., D. A. Price, T. W. Schacker, T. E. Asher, G. Silvestri, S. Rao, Z. Kazzaz, E. Bornstein, O. Lambotte, D. Altmann, et al 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12: 1365-1371. [Medline]
55. Kaufmann, D. E., D. G. Kavanagh, F. Pereyra, J. J. Zaunders, E. W. Mackey, T. Miura, S. Palmer, M. Brockman, A. Rathod, A. Piechocka-Trocha, et al 2007. Upregulation of CTLA-4 by HIV-specific CD4⁺ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8: 1246-1254. [Medline]
56. Hel, Z., J. M. Johnson, E. Tryniszewska, W. P. Tsai, R. Harrod, J. Fullen, J. Tartaglia, G. Franchini. 2002. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. Vaccine 20: 3171-3186. [Medline]

This article has been cited by other articles:

				D. E. Kaufmann and B. D. Walker PD-1 and CTLA-4 Inhibitory Cosignaling Pathways in HIV Infection and the Potential for Therapeutic Intervention J. Immunol., May 15, 2009; 182(10): 5891 - 5897. [Abstract] [Full Text] [PDF]

				Y. Wang, S. A. Blozis, M. Lederman, A. Krieg, A. Landay, and C. J. Miller Enhanced Antibody Responses Elicited by a CpG Adjuvant Do Not Improve the Protective Effect of an Aldrithiol-2-Inactivated Simian Immunodeficiency Virus Therapeutic AIDS Vaccine Clin. Vaccine Immunol., April 1, 2009; 16(4): 499 - 505. [Abstract] [Full Text] [PDF]

				A. Boasso, M. Vaccari, D. Fuchs, A. W. Hardy, W.-P. Tsai, E. Tryniszewska, G. M. Shearer, and G. Franchini Combined Effect of Antiretroviral Therapy and Blockade of IDO in SIV-Infected Rhesus Macaques J. Immunol., April 1, 2009; 182(7): 4313 - 4320. [Abstract] [Full Text] [PDF]

				B. Malleret, B. Maneglier, I. Karlsson, P. Lebon, M. Nascimbeni, L. Perie, P. Brochard, B. Delache, J. Calvo, T. Andrieu, et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression Blood, December 1, 2008; 112(12): 4598 - 4608. [Abstract] [Full Text] [PDF]

				M. Genesca, P. J. Skinner, J. J. Hong, J. Li, D. Lu, M. B. McChesney, and C. J. Miller With Minimal Systemic T-Cell Expansion, CD8+ T Cells Mediate Protection of Rhesus Macaques Immunized with Attenuated Simian-Human Immunodeficiency Virus SHIV89.6 from Vaginal Challenge with Simian Immunodeficiency Virus J. Virol., November 15, 2008; 82(22): 11181 - 11196. [Abstract] [Full Text] [PDF]

				I. Pandrea, T. Gaufin, J. M. Brenchley, R. Gautam, C. Monjure, A. Gautam, C. Coleman, A. A. Lackner, R. M. Ribeiro, D. C. Douek, et al. Cutting Edge: Experimentally Induced Immune Activation in Natural Hosts of Simian Immunodeficiency Virus Induces Significant Increases in Viral Replication and CD4+ T Cell Depletion J. Immunol., November 15, 2008; 181(10): 6687 - 6691. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cecchinato, V. Articles by Franchini, G. Search for Related Content PubMed PubMed Citation Articles by Cecchinato, V. Articles by Franchini, G.